Renaud L, Chaillol I, Galtier J, Bommier C, Tessoulin B, de Colella JMS, Lamy T, Borel C, Stamatoullas A, Gac AC, Morschhauser F, Andre M, Ghesquieres H, Traverse-Glehen A, Casasnovas O, Gastine T. Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial. Haematologica; https://doi.org/10.3324/haematol.2026.301194 [Early view].